Idebenone-Activating Autophagic Degradation of <i>α</i>-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson’s Disease: A Network Pharmacological Approach

<div>Network pharmacology analysis of the putative targets of Idebenone against Parkinson’s disease. (a) The protein-protein interaction (PPI) network of the candidate protein targets of Idebenone. The nodes represent different proteins and the edges represent the association between them. The thickness of the interconnection between nodes indicates the strength of the evidence. (b) The hub genes (AKT1, MAPK1, PIK3CA, EGFR, APP, and AKT2) with a high degree value were screened from the PPI network analysis.</div>

Evidence-Based Complementary and Alternative Medicine

fig3

Figure 3

Figure 3: Idebenone-Activating Autophagic Degradation of <i>α</i>-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson’s Disease: A Network Pharmacological Approach 

Figure 3 | Idebenone-Activating Autophagic Degradation of α-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson’s Disease: A Network Pharmacological Approach 